机构:[1]Department of Pharmaceutics, Shenyang Pharmaceutical University, Wenhua Road 103, Shenyang 110016, PR China[2]New Drug Research and Development Center, North China Pharmaceutical Group Corporation, Heping East Road 388, Shijiazhuang 050015, PR China[3]Department of Medical Oncology, The Forth Hospital of Hebei Medical University, Jiankang Road 12, Shijiazhuang 050011, PR China临床科室肿瘤内科河北医科大学第四医院[4]Benyuan Nano-Instruments Corporation Ltd., Xianliezhong Road 100, Guangzhou 510070, PR China
Venous malformations (VM) are common vascular abnormality, and their management remains difficult. Pingyangmycin hydrochloride (PYM) is a useful sclerosant to treat venous malformations. This study was aimed to evaluate the effect of a new drug delivery system, PYM-loaded Zein/Zein-sucrose acetate isobutyrate (SAIB) in situ gels, in gelling and extending the local release of PYM. It was demonstrated that in vitro and in vivo release of PYM from the in situ gels could be extended up to 7 and 4 days, respectively. SAIB could significantly cut down the initial burst of PYM from the in situ gels (P < 0.05). The possible gel forming and drug release mechanisms were described according to the morphology analysis by atomic force microscopy (AFM), optical microscopy and SEM. The gel forming efficacy and the viscosity of in situ get solutions were satisfying (c) 2006 Elsevier B.V. All rights reserved.
第一作者机构:[1]Department of Pharmaceutics, Shenyang Pharmaceutical University, Wenhua Road 103, Shenyang 110016, PR China
通讯作者:
推荐引用方式(GB/T 7714):
Gao Zibin,Ding Pingtian,Zhang Li,et al.Study of a Pingyangmycin delivery system: Zein/Zein-SAIB in situ gels[J].INTERNATIONAL JOURNAL OF PHARMACEUTICS.2007,328(1):57-64.doi:10.1016/j.ijpharm.2006.07.048.
APA:
Gao, Zibin,Ding, Pingtian,Zhang, Li,Shi, Jian,Yuan, Shuqin...&Chen, Dawei.(2007).Study of a Pingyangmycin delivery system: Zein/Zein-SAIB in situ gels.INTERNATIONAL JOURNAL OF PHARMACEUTICS,328,(1)
MLA:
Gao, Zibin,et al."Study of a Pingyangmycin delivery system: Zein/Zein-SAIB in situ gels".INTERNATIONAL JOURNAL OF PHARMACEUTICS 328..1(2007):57-64